Chengdu Benefit Technology Co., Ltd. – Trademark Portfolio

Entity Type: 03

Chengdu Benefit Technology Co., Ltd. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 2 filings in this category. Currently, 1 trademark is registered. Notable registered marks include ELITOPT. The owner is based in Chengdu.

Tianfuxinqu Huayang St Tianfu Road S 888

Chengdu 610213 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ELITOPT
ELITOPT
Registered 2019
ELITOPT
ELITOPT
Abandoned 2019

Trademark Classifications

Chengdu Benefit Technology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

9
Computers & Electronics (2 filings)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

Frequently Asked Questions

How many trademarks does Chengdu Benefit Technology Co., Ltd. have?

Chengdu Benefit Technology Co., Ltd. has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned.

What trademark classes does Chengdu Benefit Technology Co., Ltd. file in?

Chengdu Benefit Technology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 9 (Computers & Electronics). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.

What are Chengdu Benefit Technology Co., Ltd.'s most well-known trademarks?

Chengdu Benefit Technology Co., Ltd.'s registered trademark portfolio includes well-known marks such as ELITOPT. These are among 1 currently registered trademark in the portfolio.

What is Chengdu Benefit Technology Co., Ltd.'s trademark registration success rate?

Chengdu Benefit Technology Co., Ltd. has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.